Search research articles
Contact Us
Filters
Showing results (671-680 of 696) with videos related to
Page
of 70
Sort By:
JAMA Internal Medicine
|
February 10, 2016
Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure: The Better Effectiveness After Transition -- Heart Failure (BEAT-HF) Randomized Clinical Trial
Michael K Ong, Patrick S Romano, Sarah Edgington, et al.
Plos One
|
March 3, 2022
Clinically adjudicated deceased donor acute kidney injury and graft outcomes
Sherry G Mansour, Nadeen Khoury, Ravi Kodali, et al.
Circulation
|
May 20, 1999
Thrombogenic factors and recurrent coronary events
A J Moss, R E Goldstein, V J Marder, et al.
Physical Review Letters
|
December 31, 2008
Experimental constraints on a dark matter origin for the DAMA annual modulation effect
C E Aalseth, P S Barbeau, D G Cerdeño, et al.
Nature
|
September 21, 2023
A multi-stem cell basis for craniosynostosis and calvarial mineralization
Seoyeon Bok, Alisha R Yallowitz, Jun Sun, et al.
Lancet (London, England)
|
November 13, 2012
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
John R Teerlink, Gad Cotter, Beth A Davison, et al.
Journal of the American Society of Nephrology : JASN
|
October 30, 2020
Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study
Sarah J Schrauben, Haochang Shou, Xiaoming Zhang, et al.
Journal of the American College of Cardiology
|
January 1, 2013
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes
Marco Metra, Gad Cotter, Beth A Davison, et al.
Lancet (London, England)
|
August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
John G F Cleland, John R Teerlink, Roxy Senior, et al.
BMC Neurology
|
April 10, 2021
Blood flow response to orthostatic challenge identifies signatures of the failure of static cerebral autoregulation in patients with cerebrovascular disease
Clara Gregori-Pla, Rickson C Mesquita, Christopher G Favilla, et al.
Page
of 70
Search research articles
Search
Showing results (671-680 of 696) with videos related to
Sort By:
Page
of 70
JAMA Internal Medicine
|
February 10, 2016
Effectiveness of Remote Patient Monitoring After Discharge of Hospitalized Patients With Heart Failure: The Better Effectiveness After Transition -- Heart Failure (BEAT-HF) Randomized Clinical Trial
Michael K Ong, Patrick S Romano, Sarah Edgington, et al.
Plos One
|
March 3, 2022
Clinically adjudicated deceased donor acute kidney injury and graft outcomes
Sherry G Mansour, Nadeen Khoury, Ravi Kodali, et al.
Circulation
|
May 20, 1999
Thrombogenic factors and recurrent coronary events
A J Moss, R E Goldstein, V J Marder, et al.
Physical Review Letters
|
December 31, 2008
Experimental constraints on a dark matter origin for the DAMA annual modulation effect
C E Aalseth, P S Barbeau, D G Cerdeño, et al.
Nature
|
September 21, 2023
A multi-stem cell basis for craniosynostosis and calvarial mineralization
Seoyeon Bok, Alisha R Yallowitz, Jun Sun, et al.
Lancet (London, England)
|
November 13, 2012
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
John R Teerlink, Gad Cotter, Beth A Davison, et al.
Journal of the American Society of Nephrology : JASN
|
October 30, 2020
Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study
Sarah J Schrauben, Haochang Shou, Xiaoming Zhang, et al.
Journal of the American College of Cardiology
|
January 1, 2013
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes
Marco Metra, Gad Cotter, Beth A Davison, et al.
Lancet (London, England)
|
August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
John G F Cleland, John R Teerlink, Roxy Senior, et al.
BMC Neurology
|
April 10, 2021
Blood flow response to orthostatic challenge identifies signatures of the failure of static cerebral autoregulation in patients with cerebrovascular disease
Clara Gregori-Pla, Rickson C Mesquita, Christopher G Favilla, et al.
Page
of 70